NEWLY DIAGNOSED NEOPLASIA IN CROHN DISESE PATIENTS TREATED WITH INFLIXIMAB;A 1 YEAR LONGER FOLLOW UP FROM A MULTICENTER MATCHED PAIR STUDY

1. Inflamm Bowel Dis. 2011 Mar;17(3):758-66. doi: 10.1002/ibd.21416.Cancer in Crohn's Disease patients treated with infliximab: a long-termmulticenter matched pair study.Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G,Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F.GI Unit, University, Tor Vergata, Roma. biancone@med.uniroma2.itBACKGROUND: The long-term risk of neoplasia in Crohn's disease (CD) patientstreated with infliximab is undefined. The aim was to assess, in a multicenter,matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term.METHODS: A multicenter, long-term, matched-pair study was conducted in 12referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CDpatients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controlsnever treated with infliximab (CD-C) studied from 1999 to 2004, was followed upfor an additional 4 years (2004-2008). Cases and controls were matched for: sex, age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CDduration (±5 years). From 1999 to 2008 the frequency and characteristics ofneoplasia were compared between CD-IFX and CD-C.RESULTS: In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months:72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency ofneoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94%)and CD-C (12/287; 4.19%; P = 0.95). A comparable frequency of neoplasia was also observed between the 221 matched couples (CD-IFX: 8/221; 3.61% versus CD-C:9/221; 4.07%; P = 1). No specific histotype of cancer appeared associated withinfliximab use.CONCLUSIONS: The frequency of neoplasia was comparable in an adult population of CD patients treated or not with infliximab, matched for clinical variables andfollowed up for a median of 6 years.Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.PMID: 20684009 [PubMed - indexed for MEDLINE]